Primary myelofibrosis with concurrent paroxysmal nocturnal haemoglobinuria presenting with erectile dysfunction

Zaenb Alsalman¹*, Mortadah Alsalman ², Mohammed Albesher³, Alaa Alsalman³, Sultan Saif⁴, Ali Aldandan⁴ and Ahmed Alsuliman³

¹Departments of Family Medicine, King Faisal University, Eastern Province, Saudi Arabia
²Departments of Medicine, King Faisal University, Eastern Province, Saudi Arabia
³Departments of Medicine, Prince Saud Bin Jalawi Hospital, Eastern Province, Saudi Arabia
⁴Departments of Pathology, Prince Saud Bin Jalawi Hospital, Eastern Province, Saudi Arabia

*Correspondence address: College of Medicine, King Faisal University, Po Box 3311, Al Hasa 36346, Saudi Arabia. Tel: +966545611633; E-mail: Alsalman.zainab@hotmail.com, ORCID iD 0000-0002-1008-7977

Abstract

Primary myelofibrosis and paroxysmal nocturnal haemoglobinuria (PNH) are uncommon clonal blood disorders that are rarely found together. We report a case of primary myelofibrosis (PMF) with concomitant subtle PNH in a 42-year-old man who presented with a 4-week history of fatigue, unexplained chest pain, and new-onset erectile dysfunction. Bone marrow biopsy showed severe fibrosis consistent with PMF. However, smooth muscle dystonia symptoms in the form of new-onset erectile dysfunction and oesophageal spasm were not fully explained by PMF but were clues for PNH, confirmed by flow cytometric assays. Routine PNH testing for patients with new-onset PMF and clinical symptoms suggestive of PNH, as well as those with refractory anaemia despite effective therapy, is crucial since these two conditions can coexist. As a result, a lack of early testing may cause a delay in diagnosis, increasing the patient’s transfusion load and the facility’s costs.

INTRODUCTION

Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal blood disorder due to somatic mutation of the phosphatidylinositol glycan class A (PIG-A). It is characterized by intravascular haemolysis, bone marrow failure and increased risk of thrombosis as well as smooth muscle dystonia. There is an intimate overlap between aplastic anaemia and PNH, with 40–60% of patients with aplastic anaemia having a PNH clone. However, there is an anecdotal report about a similar overlap between PNH and other marrow disorders [1, 2]. We report a case of primary myelofibrosis (PMF) with concomitant subtle PNH predicted by the presence of new-onset erectile dysfunction.

CASE REPORT

This is a 42-year-old man who presented with a 4-week history of fatigue, tiredness and on-and-off central chest pain. These symptoms were associated with a new-onset 6-week history of erectile dysfunction and loss of morning erection even though he and his wife have a good relationship. He had sought medical advice several times and received blood transfusions, with an insignificant transient response. His sister had been diagnosed with acute leukaemia at the age of 40, and she had passed away several months post-allogeneic stem cell transplantation. Clinical examination revealed pale conjunctiva along with non-tender palpable spleen approximately 4 cm below the left costal margin. However, the remainder of the physical examination was unremarkable.

At that moment, his total blood count showed haemoglobin of 6 g/dL, MCV of 85 fL, a reticulocyte count of 1.2% that was initially elevated but declined with time, a platelet count of 35 × 10⁹/L and a white blood cell count of 3.700 × 10⁹/L, with an absolute neutrophil count of 1.22 × 10⁹/L. Both direct and indirect antiglobulin (Coombs) tests were negative (Table 1). A peripheral blood smear showed anisopoikilocytosis, teardrop cell and polychromasia. The other laboratory findings were as follows: serum lactic dehydrogenase (LDH) 600 units/L, total bilirubin 14.9 μmol/L, iron serum 43.55 μmol/L, iron-binding capacity total 50.40 μmol/L,
Table 1. Laboratory parameters on initial presentation

| Parameter                                    | On presentation | Reference range |
|----------------------------------------------|-----------------|-----------------|
| Haemoglobin g/dL                             | 6               | 13.5–16.5       |
| WBC $\times 10^9$/L                          | 3.7             | 4.0–10.5        |
| Platelet $\times 10^9$/L                      | 350             | 150–400         |
| Iron serum $\mu$mol/L                        | 43.55           | 6–27            |
| Ferritin ng/mL                                | 3239            | 50–200          |
| Iron-binding capacity total $\mu$mol/L       | 50.40           | 47–80           |
| Folate serum ng/mL                           | 11.83           | 3–18            |
| Total bilirubin $\mu$mol/L                   | 14.9            | 0–17            |
| Lactate dehydrogenase (LDH) units/L          | 600             | 135–225         |
| Retic count (%)                              | 1.2%            | ≤1.2%           |
| Direct Coombs test (direct antiglobulin test) | Negative        | Negative        |
| Indirect Coombs test (indirect antiglobulin test) | Negative        | Negative        |
| Hepatitis B surface antigen                  | Negative        | Negative        |
| Hepatitis C antigen                          | Negative        | Negative        |

ferritin 3239 ng/mL and folate serum 11.83 ng/mL; hepatitis B surface antigen and hepatitis C antigen were both negative (Table 1).

Both the electrocardiogram and the chest x-ray were normal. Additionally, clinical and laboratory assessments for erectile dysfunction, including total testosterone level, lipid panel, fasting serum glucose level and thyroid-stimulating hormone, were done and found to be normal. Bone marrow biopsy revealed a hypocellular marrow with remarkable infiltration by dysmorphic megakaryocytes, some active myelopoiesis and erythropoiesis and severe fibrosis (mf 2.5) (Figs 1–3). A molecular study revealed positive CALR, whereas BCR-ABL, JAK2 and MPL were not detected. Further, the chromosomal analysis revealed t (12,13) and classified under a high-risk category of primary myelofibrosis based on both the Dynamic International Prognostic Scoring System (DIPSS) and Genetically Inspired Prognostic Scoring System (GIPSS) [3]. The presence of non-cardiac chest pain and new-onset erectile dysfunction in the context of bone marrow failure raised the possibility of PNH, where nitric oxide is expected to be depleted, resulting in vasoconstriction. Flow cytometric assays from peripheral blood revealed 83.3% CD59-negative granulocytes and 0.03% CD59-negative red blood cells consistent with a diagnosis of PNH.

Following confirmation of diagnosis and risk stratification, the patient was transferred to another centre for allogeneic hematopoietic stem cell transplantation with the aim of prolonging survival and increasing the possibility of cure.

DISCUSSION

Paroxysmal nocturnal haemoglobinuria (PNH) is a clonal hematopoietic stem cell disorder with heterogeneous clinical presentations. Therefore, the International PNH
Interest Group classifies it into three categories. The classical presentation is intravascular haemolysis accompanied by unusual site thrombosis or smooth muscle dystonia in the form of abdominal pain, oesophageal spasm, or erectile dysfunction. The other two categories are subclinical PNH and PNH in the context of marrow failure syndrome, including aplastic anaemia (AA) and myelodysplastic syndrome (MDS) [1, 4].

The International Clinical Cytometry Society (ICCS) guidelines state that all patients with thrombosis with unknown cytopenia or intravascular haemolysis should undergo PNH screening. Additionally, ICCS recommends screening all patients with AA and MDS, even in the absence of haemolysis [5].

Several case reports indicate the coexistence of PNH with PMF and other myeloproliferative neoplasms (MPN). Some of these cases were harbouring either JAK2V617F or CALR mutations in their PNH clone. However, most of these cases were diagnosed with PNH several years after being diagnosed with one of the MPNs. These findings support the hypothesis that clinically significant PNH results from a stepwise progression of multiple genetic mutations like MDS or MPN [6, 7].

To our knowledge, this is the third case where PNH is present simultaneously with PMF. Previously reported cases presented with overt PNH in the form of haemoglobinuria and thrombosis. Unlike previously reported cases, PNH diagnosis in our patient was easy to miss due to a lack of laboratory evidence of haemolysis. Moreover, flow cytometry findings in this patient were misleading. They showed a discrepancy between red and white blood cells' PNH clones, but this is likely attributed to prior blood transfusion and ongoing subtle haemolysis. On the other hand, smooth muscle dystonia symptoms in the form of oesophageal spasm and erectile dysfunction were clues for PNH diagnosis.

Routine PNH testing for patients with new-onset primary myelofibrosis and clinical symptoms suggestive of PNH, as well as those with refractory anaemia despite effective therapy, is crucial since these two conditions can coexist. As a result, a lack of early testing may cause a delay in diagnosis, increasing the patient’s transfusion load and the facility’s costs. Conversely, the process of thrombosis in an unusual site in PNH patients is not fully explained, and whether the coexistence of MPN causes this is an area for further research.

CONCLUSION
PNH is a clonal hematopoietic stem cell disorder with subtle, heterogeneous presentation, particularly if it coexists with other bone marrow disorders. PNH testing is recommended for patients with a previous diagnosis of AA, MDS, as well as those who have thrombosis with unknown cytopenia or intravascular haemolysis. Hence, additional studies are needed to better understand the association between PNH and MPN and whether all or only certain groups of patients need to be screened for PNH and vice versa.

ACKNOWLEDGEMENT
Thanks to the patient for allowing us to share this case with the scientific community.

CONFLICT OF INTEREST STATEMENT
No conflict of interest to disclose.

FUNDING
No financial support for the research, authorship, or publication of this case report.

CONSENT
Written informed consent was obtained from the patient to publish this case report and images in this journal.

REFERENCES
1. Almomen AK, Al Bakistani AG, Alsaed A, Alolama A, Hejazi A, Awarji C et al. Paroxysmal nocturnal hemoglobinuria: Diagnosis and management protocol. J Appl Hematology 2014;5:37–44.
2. Griffin M, Kulasekararaj A, Gandhi S, Munir T, Richards S, Arnold L et al. Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: A UK experience. Haematologica 2018;103:345–7.
3. Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM. Myelofibrosis Treatment Algorithm 2018. Blood Cancer J 2018;8:72.
4. Dezern AE, Borowitz MJ. ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria (PNH) and related disorders part 1 – clinical utility. Cytometry B Clin Cytom 2018;94:16–22.
5. Fraiman YS, Cuca N, Batista D, Vuica-Ross M, Moliterno AR. Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasms. J Blood Med 2016;7:107–10.
6. Nishimura JI. Paroxysmal nocturnal hemoglobinuria. Rinsho Ketsueki 2012;53:15–24.
7. Sugimori C, Padrón E, Caceres G, Shain K, Sokol L, Zhang L et al. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2 V617F mutation. Blood Cancer J 2012;2:1–4.